- Type / Class
- Equity / Common Stock
- Shares outstanding
- 58,974,400
- Total 13F shares
- 50,216,931
- Share change
- +3,226,405
- Total reported value
- $2,771,120,513
- Put/Call ratio
- 100%
- Price per share
- $55.19
- Number of holders
- 164
- Value change
- +$171,282,810
- Number of buys
- 100
- Number of sells
- 85
Quarterly Holders Quick Answers
What is CUSIP 03940C100?
CUSIP 03940C100 identifies ACLX - Arcellx, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 03940C100:
Top shareholders of ACLX - Arcellx, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
|
Company |
9.1%
|
5,394,495
|
$375,187,128 | — | 31 Mar 2024 | |
| GILEAD SCIENCES, INC. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
6,720,803
|
$371,444,668 | — | 28 Dec 2023 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
6.7%
|
3,933,556
|
$273,578,820 | — | 31 Mar 2024 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
6.5%
|
3,818,095
|
$265,548,507 | — | 31 Mar 2024 | |
| NEA Partners 15, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,745,262
|
$262,260,666 | — | 20 Dec 2022 | |
| New Enterprise Associates 15, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,745,262
|
$262,260,666 | — | 20 Dec 2022 | |
| NEA Management Company, LLC |
13F
|
Company |
6.4%
|
3,745,262
|
$260,482,972 | — | 31 Mar 2024 | |
| Novo Holdings A/S |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,016,878
|
$222,004,412 | — | 08 Feb 2022 | |
| BlackRock Finance, Inc. |
13F
|
Company |
5.2%
|
3,066,068
|
$213,245,028 | — | 31 Mar 2024 | |
| SR ONE CAPITAL MANAGEMENT, LP |
13F
|
Company |
4%
|
2,346,630
|
$163,208,117 | — | 31 Mar 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.8%
|
2,228,856
|
$155,016,934 | — | 31 Mar 2024 | |
| STATE STREET CORP |
13F
|
Company |
3.2%
|
1,885,118
|
$131,109,957 | — | 31 Mar 2024 | |
| Cormorant Asset Management, LP |
13F
|
Company |
3%
|
1,780,000
|
$123,799,000 | — | 31 Mar 2024 | |
| Lewis T. "rusty" Williams |
3/4/5
|
Director |
—
class O/S missing
|
2,095,114
|
$115,792,551 | — | 08 Feb 2022 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.6%
|
1,562,354
|
$108,661,721 | — | 31 Mar 2024 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
2.6%
|
1,522,309
|
$105,856,303 | — | 31 Mar 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
2.3%
|
1,344,553
|
$93,514,000 | — | 31 Mar 2024 | |
| SR ONE CAPITAL MANAGEMENT, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,658,780
|
$91,677,287 | — | 11 May 2023 | |
| LORD, ABBETT & CO. LLC |
13F
|
Company |
2%
|
1,198,117
|
$83,329,000 | — | 31 Mar 2024 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
1.7%
|
982,862
|
$68,359,000 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.4%
|
838,469
|
$58,322,941 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
1.2%
|
696,762
|
$48,459,841 | — | 31 Mar 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.94%
|
551,750
|
$38,374,213 | — | 31 Mar 2024 | |
| Samsara BioCapital, LLC |
13F
|
Company |
0.77%
|
453,641
|
$31,550,732 | — | 31 Mar 2024 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.76%
|
447,783
|
$31,143,308 | — | 31 Mar 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.7%
|
414,541
|
$28,831,326 | — | 31 Mar 2024 | |
| VOYA INVESTMENT MANAGEMENT LLC |
13F
|
Company |
0.65%
|
382,558
|
$26,606,909 | — | 31 Mar 2024 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.62%
|
363,093
|
$25,253,118 | — | 31 Mar 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.61%
|
359,460
|
$25,000,443 | — | 31 Mar 2024 | |
| PFM Health Sciences, LP |
13F
|
Company |
0.51%
|
303,210
|
$21,088,256 | — | 31 Mar 2024 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.51%
|
300,000
|
$20,865,000 | — | 31 Mar 2024 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
0.51%
|
300,000
|
$20,865,000 | — | 31 Mar 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.48%
|
282,010
|
$19,613,796 | — | 31 Mar 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.46%
|
272,793
|
$18,972,753 | — | 31 Mar 2024 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.46%
|
272,009
|
$18,918,226 | — | 31 Mar 2024 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
0.45%
|
265,410
|
$18,459,265 | — | 31 Mar 2024 | |
| Integral Health Asset Management, LLC |
13F
|
Company |
0.43%
|
255,000
|
$17,735,250 | — | 31 Mar 2024 | |
| BAMCO INC /NY/ |
13F
|
Company |
0.42%
|
248,993
|
$17,317,463 | — | 31 Mar 2024 | |
| VICTORY CAPITAL MANAGEMENT INC |
13F
|
Company |
0.4%
|
235,866
|
$16,404,480 | — | 31 Mar 2024 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.39%
|
231,661
|
$16,112,023 | — | 31 Mar 2024 | |
| S.c.a. Candriam |
13F
|
Individual |
0.37%
|
220,008
|
$15,301,556 | — | 31 Mar 2024 | |
| EAGLE ASSET MANAGEMENT INC |
13F
|
Company |
0.38%
|
224,534
|
$15,039,287 | — | 31 Mar 2024 | |
| Russell Investments Group, Ltd. |
13F
|
Company |
0.33%
|
195,437
|
$13,592,669 | — | 31 Mar 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.32%
|
188,854
|
$13,134,796 | — | 31 Mar 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.32%
|
186,783
|
$12,990,757 | — | 31 Mar 2024 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.27%
|
156,598
|
$10,891,391 | — | 31 Mar 2024 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
0.25%
|
150,000
|
$10,432,500 | — | 31 Mar 2024 | |
| STEMPOINT CAPITAL LP |
13F
|
Company |
0.24%
|
140,267
|
$9,755,570 | — | 31 Mar 2024 | |
| Rafferty Asset Management, LLC |
13F
|
Company |
0.21%
|
126,751
|
$8,815,532 | — | 31 Mar 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.21%
|
121,064
|
$8,420,002 | — | 31 Mar 2024 |
Institutional Holders of Arcellx, Inc. - Common Stock (ACLX) as of Q2 2024
As of 30 Jun 2024,
Arcellx, Inc. - Common Stock (ACLX) was held by
164 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
50,216,931 shares.
The largest 10 holders included
FMR LLC, PERCEPTIVE ADVISORS LLC, Paradigm Biocapital Advisors LP, NEA Management Company, LLC, BlackRock Inc., SR One Capital Management, LP, VANGUARD GROUP INC, JANUS HENDERSON GROUP PLC, STATE STREET CORP, and PRICE T ROWE ASSOCIATES INC /MD/.
This page lists
164
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
180
Q2 2024 holders
164
Holder diff
-16
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.